Intuitively, systemic therapy should be a crucial component of care for patients with brain metastases from HER2-positive breast cancer, considering that many of these patients will harbour distant metastases outside of the brain which also need to be treated to achieve long-term survival. In Thomas Bachelot and colleagues' phase 2 study, 45 patients with previously untreated brain metastases from HER2-positive breast cancer were treated with capecitabine and lapatinib. As discussed by the authors, previous studies suggested that these drugs are active against extracranial and intracranial metastases.
Júlio Leonardo B. Pereira
No comments:
Post a Comment